Dechra
They may be small, but their treatment is now mighty.
VETORYL®
Capsules (trilostane) are now available in a 5mg strength.
Your smaller patients can now receive the same effective, FDA-approved treatment for their Cushing’s syndrome as you’ve trusted for your larger patients.
VETORYL Capsules are the only FDA veterinary-approved treatment for pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs (Cushing’s syndrome). They contain the active ingredient trilostane, which blocks the excessive production of cortisol.
As with all drugs, side effects may occur. In fi eld studies and post-approval experience, the most common side effects reported were: anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insuffi ciency. In some cases, death has been reported as an outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs. Refer to the prescribing information for complete details or visit
www.Dechra-US.com.
24 Hour Technical Support: 866-933-2472 |
www.dechra-us.com |
support@dechra.com
VETORYL is a trademark of Dechra LTD. ©2015, Dechra Ltd. NADA 141-291, Approved by FDA
CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian. 1
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm049823.htm
Dechra Veterinary Products US and the Dechra D logo are registered trademarks of Dechra Pharmaceuticals PLC.
18
Insight
800.225.7911
Patterson Veterinary Signature Brands and Exclusive Products
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36